Lundbeck 2Q: Raised Revenues But Rocky Route Ahead
Executive Summary
Lundbeck is on the road to recovery following two years under new CEO Kåre Schultz's reign and somewhat decent Q2 results, but to secure long-term sustainability and yield riper fruit for the future, the company needs to consider striking bold partnerships and bolstering its pipeline.
You may also be interested in...
China Approves Lundbeck Antidepressant In Year-End Dash
China FDA greenlights Lundbeck's Brintellix for severe depression, and more new drug approvals may be on the way. Physician education will be key for Brintellix, given relatively low number of psychiatrists in China.
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.